Literature DB >> 20037899

Use of amniotic membrane transplantation in isolated conjunctival Bowen disease: a case report.

Ilaria Motolese1, Luigi Mazzera, Paolo Frezzotti, Paolo Alfonso Motolese, Eduardo Motolese.   

Abstract

PURPOSE: To report a case of isolated conjunctival Bowen disease treated with surgical resection and amniotic membrane transplantation.
METHODS: Interventional case report.
RESULTS: A 70-year-old man was admitted to our clinic with a large conjunctival verrucous plaque well-demarcated in the correspondence of the bulbar conjunctiva in the superior quadrant of the left eye with involved limbal and corneal surface. Ophthalmologic examination on slit-lamp examination and color fundus photographs were carried out before surgery and the results were evaluated.
CONCLUSIONS: Treatment options and treatment studies of Bowen disease are difficult because there are a variety of different protocols and the success of the management depends on several factors (body site, lesion size, number of lesions, and thickness). In the conjunctival localization of the lesion, amniotic membrane transplantation appears to be a useful therapeutic choice after surgical resection of the lesion used to reconstruct ocular and conjunctival surface.

Entities:  

Mesh:

Year:  2010        PMID: 20037899     DOI: 10.1177/112067211002000313

Source DB:  PubMed          Journal:  Eur J Ophthalmol        ISSN: 1120-6721            Impact factor:   2.597


  2 in total

1.  Sutureless amniotic membrane transplantation following excision of ocular surface neoplasia.

Authors:  Altan Ozcan; Ebru Esen; Emine Ciloglu
Journal:  Int J Ophthalmol       Date:  2015-06-18       Impact factor: 1.779

2.  Immunosuppressive potential of human amnion epithelial cells in the treatment of experimental autoimmune encephalomyelitis.

Authors:  Courtney A McDonald; Natalie L Payne; Guizhi Sun; Leon Moussa; Christopher Siatskas; Rebecca Lim; Euan M Wallace; Graham Jenkin; Claude C A Bernard
Journal:  J Neuroinflammation       Date:  2015-06-03       Impact factor: 8.322

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.